HOME >> BIOLOGY >> NEWS
Accentia Biopharmaceuticals announces option agreement with Mayo

(NASDAQ : ABPI) announced today that it has signed an option agreement with the Mayo Foundation for Medical Education and Research for the exclusive right to negotiate a license for a method of use for any and all antifungals other than amphotericin B applied intranasally for the treatment of chronic sinusitis, sometimes known as chronic rhinosinusitis. If unexercised, the option expires on December 6, 2006. Accentia has previously obtained a worldwide exclusive license for the method of use, utilizing the antifungal, amphotericin B, for this indication. Accentia is developing a unique formulation of amphotericin B for intranasal application for the treatment of chronic sinusitis under an Investigational New Drug Application (IND).

Chronic sinusitis affects an estimated 31 million Americans. The symptoms are three or more months of chronic nasal obstruction, nasal discharge, and periocular headaches or pressure sensation. The symptoms of chronic inflammation could include the growth of inflammatory polyps in the nose, and recurrent bouts of acute bacterial sinusitis. There is no approved pharmaceutical for the indication of chronic sinusitis. Many patients with severe disease resort to sinus surgery in an attempt to relieve nasal obstruction and improve sinus drainage. The Mayo Clinic researchers have identified a ubiquitous air-borne fungus in the mucus of the nose and sinuses that elicits an inflammatory response in susceptible patients. Published studies at the Mayo Clinic and elsewhere have demonstrated a significant improvement in signs and symptoms of chronic sinusitis in patients treated with intranasal amphotericin B.

"We are working diligently to develop the Mayo patented technology for the treatment of chronic sinusitis with intranasal amphotericin B," said Steve Arikian, MD, President and COO of Accentia's Product Development and Market Services. "We recognized that our impending clinical trials of amphotericin B for this indication, if
'"/>

Contact: Sherran Brewer
sbrewer@accentia.net
866-481-9020
SciWords
15-Dec-2005


Page: 1 2

Related biology news :

1. FDA grants Accentia Biopharmaceuticals...
2. AutovaxID-C introduced by Accentia Biopharmaceuticals
3. Accentia Biopharmaceuticals acquires exclusive license
4. Accentia Biopharmaceuticals, Inc. launches CRSFungal Profile
5. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
6. ESA announces 2007 award recipients
7. President Bush announces 2005 and 2006 Laureates of National Medals of Science and Technology
8. Conservation Leadership Program announces 2007 awardees
9. ACMG Foundation announces 2007-2008 Luminex/ACMGF award recipient
10. Revolutionary global environment fund announces $50M expansion
11. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/1/2020)... SOMERSET, N.J. (PRWEB) , ... July 01, 2020 ... ... today announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility ... with the company’s existing Japanese clinical supply facility located in Kakegawa, the new ...
(Date:6/25/2020)... ... June 24, 2020 , ... ... software-driven clinical data services that accelerate drug development, is collaborating with Karyopharm Therapeutics ... inhibitor, in hospitalized patients with severe COVID-19. This is the first study of ...
(Date:6/23/2020)... WOODLNDS, Texas (PRWEB) , ... June 23, 2020 ... ... X-ray analytical instrumentation, is pleased to announce the next event in a series ... X-ray scattering. , The TOPIQ series of webinars was developed in response to ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 30, 2020 , ... ... software for the life sciences industry, today announced the release of its ... specifically for Medical Science Liaisons (MSLs) and other field medical professionals. ...
(Date:7/18/2020)... ... 16, 2020 , ... After research model surgery and catheter implantation, the long ... only the beginning of a successful study, while protecting and accessing the catheter or ... Head of Surgery from Envigo in a live webinar on ...
(Date:7/18/2020)... ... July 16, 2020 , ... ... the early detection and prevention of high-burden diseases, and Centric Consulting, a business ... healthcare organizations to utilize existing data in order to identify and prioritize patients ...
(Date:7/10/2020)... ... July 08, 2020 , ... ... a significant expansion of laboratory operations through its COVID-19 testing service, Bode-CARES ... programs. , Bode-CARES provides a turnkey solution that includes a ...
Breaking Biology Technology:
Cached News: